Table 3.
MSC cell-based therapies with a valid marketing authorisation.
| Trade name | Company | Authorised by | Cell type | Indication |
|---|---|---|---|---|
| Hearticellgram* | FCB PharmiCell | KFDA (2011) | Autologous BM-derived MSCs | Treatment for postacute myocardial infarction |
| Cartistem* | Medipost | KFDA (2012) | Allogeneic hUCB-MSCs | Treatment of traumatic and degenerative osteoarthritis |
| Prochymal* | Osiris Therapeutics Inc. | Health Canada (2012) New Zealand (2012) |
Allogeneic BM-MSCs | Treatment of acute GvHD children who are unresponsive to steroids |
MSCs: mesenchymal stem cells; BM: bone marrow; hUCB: human umbilical cord blood; GvHD: graft-versus-host disease; KFDA: Korean Food and Drug Administration.
*SCTMP: somatic cell therapy medicinal product.